New kinase-deficient PAK2 variants associated with Knobloch syndrome type 2

Rhonda E Schnur1,2, Lukáš Dvořáček3, Louisa Kalsner4

  • 1Cooper Medical School of Rowan University, Camden, New Jersey, USA.

Clinical Genetics
|June 19, 2024
PubMed

Insights

A novel p21-activated kinase 2 (PAK2) variant causes kinase deficiency, linking PAK2 to a second form of autosomal dominant Knobloch syndrome (KNO2). This discovery advances understanding of genetic disorders affecting cytoskeleton organization.

Area of Science:

  • Genetics
  • Molecular Biology
  • Developmental Biology

Background:

  • The p21-activated kinase (PAK) family regulates cytoskeleton dynamics, crucial for cell adhesion, migration, proliferation, and apoptosis.
  • PAK2 specifically plays roles in apoptosis, angiogenesis, and endothelial cell development.
  • Knobloch syndrome is a rare genetic disorder characterized by occipital encephalocele, eye abnormalities, and developmental delay.

Purpose of the Study:

  • To investigate the role of PAK2 variants in Knobloch syndrome.
  • To identify novel genetic causes for Knobloch syndrome.
  • To elucidate the functional consequences of identified PAK2 variants.

Main Methods:

  • Genetic sequencing to identify variants in patients with Knobloch syndrome.
  • In vitro kinase activity assays to assess the functional impact of PAK2 variants.
  • Literature review of previously reported PAK2 variants associated with similar phenotypes.

Main Results:

  • A novel de novo heterozygous missense PAK2 variant, p.(Thr406Met), was identified in a newborn with Knobloch syndrome.
  • In vitro experiments demonstrated substantially impaired kinase activity for both p.(Thr406Met) and a previously reported variant p.(Asp425Asn).
  • These findings are consistent with previously reported PAK2 variants (e.g., p.(Glu435Lys)) associated with a proposed Knobloch syndrome type 2 (KNO2).

Conclusions:

  • The identified PAK2 variants support the association of PAK2 kinase deficiency with a second, autosomal dominant form of Knobloch syndrome, designated KNO2.
  • PAK2 kinase deficiency is a newly recognized cause of autosomal dominant Knobloch syndrome.
  • This study expands the genetic basis of Knobloch syndrome and highlights PAK2's critical role in development.

Related Concept Videos

Cytoskeletal Linker Proteins - Plakins01:09

Cytoskeletal Linker Proteins - Plakins

Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...
2.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.0K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K